Survey: U.S. neurologists would prescribe Leqembi if fully approved
By
Alicia Lasek
Apr 12, 2023
A “healthy proportion” of surveyed neurologists have already begun prescribing the treatment, and nearly all said they planned to do so if traditional FDA approval is granted.
Most women unaware of their Alzheimer’s risk, Cleveland Clinic survey finds
By
Alicia Lasek (f3)
Jun 30, 2022
Fully 82% of U.S. women are unaware of their relatively high odds of developing Alzheimer’s disease. And most have not addressed key risk factors with a healthcare provider.
Managing Alzheimer’s as chronic disease will require clinician, patient education, docs say
May 03, 2022
Most primary care physicians foresee a time when dementia is managed as a chronic disease, new surveys from Quest Diagnostics have found.
Two-thirds of neurologists expect to start some patients on Aduhelm next year: survey
By
Alicia Lasek
Sep 17, 2021
The outlook for the Alzheimer’s drug aducanumab (Aduhelm) is looking up, investigators say. There are small increases in the number of Aduhelm prescribers, and an uptick in patients for whom the...
Clinical briefs for Wednesday, July 13
By
Alicia Lasek (f3)
Jul 13, 2022
Brexpiprazole reduces agitation in Alzheimer’s, late-stage study finds … Seniors skipping meds due to cost, survey finds … ‘Failure to thrive’ diagnostic code for seniors is problematic and dismissive,...
Clinical Briefs for Monday, April 13
By
Alicia Lasek
Apr 12, 2020
More than 2,200 COVID-19 deaths in nursing homes … Lack of data, testing puts residents at risk of coronavirus: provider survey … More evidence found that ultrasound can aid in delivering future Alzheimer’s...
Clinical Briefs for Friday, May 22
By
Alicia Lasek
May 21, 2020
Infection control problems ‘persisted’ at nursing homes prior to pandemic: GAO … New AARP report spotlights Alzheimer’s toll on women … Emerging medical countermeasures to COVID-19 may be best...
Vascular risk factors raise odds of Alzheimer’s disease in Blacks, Hispanics: study
By
Alicia Lasek
Jan 05, 2023
Vascular risk helps to explain the outsized odds of Alzheimer’s faced by African Americans and Hispanics in the United States, a new study has found.
Medicare costs could rise by $5B annually with expanded Alzheimer’s drug coverage: study
By
Alicia Lasek
May 12, 2023
Medicare costs could rise by $2 to $5 billion a year if CMS expands its coverage for newly approved Alzheimer’s disease drug Leqembi (lecanemab), investigators say.
Hurricanes hastened the deaths of adults with dementia, study finds
By
Alicia Lasek
Mar 08, 2023
People with Alzheimer’s and related dementias (ADRD) had higher mortality rates in U.S. counties that had recently experienced a hurricane disaster, investigators report.